Clinical Trials Using Oral Azacitidine

Clinical trials are research studies that involve people. The clinical trials on this list are studying Oral Azacitidine. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-3 of 3
  • A Study of Lenalidomide and CC-486 with Radiation Therapy for the Treatment of Plasmacytoma, LENZART Study

    This trial studies how well lenalidomide, CC-486 and radiation therapy work for the treatment of plasmacytoma. Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. CC-486 is an oral form of the drug azacitidine. CC-486 works by changing the proteins produced by the cancer cells which, when CC-486 is combined with other cancer drugs, may make the cancer cells more likely to die. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving lenalidomide, CC-486 and radiation therapy may boost the immune system’s ability to identify and destroy cancer cells, which could prevent plasmacytoma from developing into multiple myeloma or prevent multiple myeloma from getting worse (progressing).
    Location: 7 locations

  • Oral Azacitidine and Salvage Chemotherapy in Treating Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma

    This phase Ib trial studies the side effects, best dose of oral azacitidine and how well it works when given together with salvage chemotherapy in treating patients with diffuse large B cell lymphoma that has come back or does not respond to treatment. Azacitidine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as rituximab, ifosfamide, carboplatin, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving oral azacitidine and salvage chemotherapy may work better in treating patients with diffuse large B cell lymphoma.
    Location: 2 locations

  • Durvalumab, Pralatrexate, Romidepsin, and Oral Azacitidine in Treating Patients with Peripheral T-Cell Lymphoma

    This phase I / IIa trial studies the side effects and best dose of durvalumab, pralatrexate, romidepsin, and oral azacitidine, and to see how well they work in treating patients with peripheral T-cell lymphoma. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Pralatrexate is a chemotherapy drug that blocks how cells are made and therefore the growth of cancer cells can be slowed, stopped, or decreased. Romidepsin is another type of chemotherapy known as HDAC (histone deacetylase) inhibitors, which blocks the function of enzymes that help remove the acetyl groups from various proteins in cells. HDAC inhibitors help stop the growth of cancer cells and can help kill the cancer cells. Oral azacitidine prevents the body from making deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) that cells need to grow, which stops the growth of cancer cells and causes them to die. It is not yet known which combination of these drugs work best in treating patients with peripheral T-cell lymphoma.
    Location: NYP / Columbia University Medical Center / Herbert Irving Comprehensive Cancer Center, New York, New York